Starling Oncology (STLN)
Community cancer-care platform combining clinics, specialty pharmacy, and value-based payer contracts.
$5.95
Pre-market−0.14 (−2.30%)
At close$6.09(+2.53%)
In millions of USD, except per-share figures
| In millions | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|
| Revenue | 137 | 142 | 147 | 161 |
| Cost of revenue | 118 | 119 | 124 | 134 |
| Gross profit | 19 | 23 | 23 | 27 |
| 27 | 30 | 30 | 32 | |
| Selling, general & administrative | 25 | 28 | 28 | 30 |
| Other expenses | 2 | 2 | 2 | 2 |
| Operating income | −8 | −7 | −7 | −5 |
| −8 | −1 | 4 | −5 | |
| Interest expense | 2 | 2 | 2 | 2 |
| Other non-operating income | 7 | −1 | −6 | 3 |
| Income before tax | −17 | −8 | −2 | −10 |
| Net income from continuing operations | −17 | −8 | −2 | −10 |
| Net income | −17 | −8 | −2 | −10 |
| EPS, basic | −$0.14 | −$0.06 | −$0.02 | −$0.08 |
| EPS, diluted | −$0.14 | −$0.06 | −$0.02 | −$0.08 |
| Weighted average shares, basic | 97 | 101 | 102 | 103 |
| Weighted average shares, diluted | 97 | 101 | 102 | 103 |
| EBITDA | −13 | −4 | 1 | −6 |
| Depreciation & amortization | 2 | 2 | 2 | 2 |
| EBIT | −15 | −6 | −1 | −8 |